<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An alteration of the blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) permeability contributes to the development of <z:hpo ids='HP_0002181'>brain edema</z:hpo> after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we evaluated the effects of 3-[2-[4-(3-chloro-2-<z:chebi fb="0" ids="52553">methylphenyl</z:chebi>)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-<z:chebi fb="0" ids="36669,36671">indazole</z:chebi> dihydrochloride 3.5 hydrate (DY-9760e), a novel calmodulin <z:chebi fb="68" ids="48706">antagonist</z:chebi>, on <z:hpo ids='HP_0002181'>brain edema</z:hpo> formation and <z:chebi fb="2" ids="33602">BBB</z:chebi> integrity in rats subjected to transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>DY-9760e (1 mg/kg/h) was intravenously infused for 6 h, starting immediately after reperfusion of a 1-h middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment with DY-9760e significantly suppressed the increase in water content and the extravasation of Evans blue dye after transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Analysis of a magnetic resonance imaging method revealed that DY-9760e significantly prevented the development of <z:hpo ids='HP_0002181'>brain edema</z:hpo> in the cortical region of the ipsilateral hemisphere </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="45951">Trifluoperazine</z:chebi>, a calmodulin <z:chebi fb="68" ids="48706">antagonist</z:chebi> that is structurally different from DY-9760e, also attenuated <z:hpo ids='HP_0002181'>brain edema</z:hpo> elicited by transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, DY-9760e and <z:chebi fb="0" ids="45951">trifluoperazine</z:chebi> reduced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha-induced hyperpermeability of <z:chebi fb="0" ids="15443">inulin</z:chebi> through a cultured brain microvascular endothelial cell monolayer, suggesting an involvement of calmodulin in the regulation of brain microvascular barrier function </plain></SENT>
<SENT sid="7" pm="."><plain>The present results demonstrate that DY-9760e ameliorates <z:hpo ids='HP_0002181'>brain edema</z:hpo> formation and suggest that this effect may be mediated in part by the inhibition of enhanced <z:chebi fb="2" ids="33602">BBB</z:chebi> permeability after ischemic insults </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, DY-9760e is expected to be a therapeutic drug for treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
</text></document>